ArticleJournal of hepatocellular carcinoma2026
Efficacy and Safety of Radiotherapy Combined with PD-1 Inhibitors and Targeted Therapy for Unresectable Hepatocellular Carcinoma: A Retrospective, Real-World Multicenter Study.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Real-world evidence concerning the triple-combination regimens of radiotherapy (RT), PD-1 inhibitors, and targeted therapy for unresectable hepatocellular carcinoma (uHCC) is limited. This study evaluated the efficacy and safety of this combination and identified predictors of survival. Patients and Methods: In this multicenter retrospective study, 122 consecutive patients with uHCC received RT combined with PD-1 inhibitors and targeted therapy were analyzed. Objective response rate (ORR), disease control rate (DCR), overall survival (OS), progression-free survival (PFS) and treatment-related adverse events (TRAEs) were calculated. Cox regression was used to identify independent prognostic factors. Subgroup analysis explored the association between immunotherapy cycles and overall survival across tumor response stratification. Results: The cohort included 53 patients with extrahepatic metastases and 48 with macrovascular invasion. Patients received RT with a median dose of 45 Gy (range: 32.3-58.5 Gy). Median follow-up was 14.2 months. According to the modified response evaluation criteria in solid tumor (mRECIST), the ORR and DCR were 18.85% and 73.78%, respectively. The median OS was 19.0 months (95% CI: 17.8-23.4 months), and the median PFS was 7.2 months (95% CI: 5.5-10.9 months). TRAEs of any grade occurred in 93 patients (76.23%), with grade 3-4 TRAEs observed in 40 patients (32.79%). No treatment-related death was observed. Multivariate analysis identified elevated AFP and higher mALBI grade as independent risk factors for OS. Higher mALBI grade and neutrophil-to-lymphocyte ratio (NLR) predicted worse PFS. Exploratory analysis suggested extending immunotherapy duration may improve OS in patients with stable disease. Conclusion: The triple-combination of RT, PD-1 inhibitors, and targeted therapy demonstrates promising survival benefits and a manageable toxicity profile for uHCC. Baseline AFP, liver function, NLR level are key determinants of survival, supporting the individualized application of this multimodal approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.